MAPT and Cognitive impairment: β-amyloid deposition and tauopathy, as assessed by levels of Aβ species and p-Tau (p-Tau 181, 217, 231), respectively, in cerebrospinal fluid (CSF) and plasma as well as directly by positron emission tomography (PET), can be used to detect Aβ- and Tau-related neuropathology prior to the onset of cognitive impairment [7].